DE69321122D1 - Selbststabilisierte oligonukleotide als therapeutika - Google Patents

Selbststabilisierte oligonukleotide als therapeutika

Info

Publication number
DE69321122D1
DE69321122D1 DE69321122T DE69321122T DE69321122D1 DE 69321122 D1 DE69321122 D1 DE 69321122D1 DE 69321122 T DE69321122 T DE 69321122T DE 69321122 T DE69321122 T DE 69321122T DE 69321122 D1 DE69321122 D1 DE 69321122D1
Authority
DE
Germany
Prior art keywords
self
stabilized
therapeutics
nucleic acid
complementary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69321122T
Other languages
English (en)
Inventor
Sudhir Agrawal
Jin-Yan Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of DE69321122D1 publication Critical patent/DE69321122D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DE69321122T 1992-07-02 1993-07-02 Selbststabilisierte oligonukleotide als therapeutika Expired - Lifetime DE69321122D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90906992A 1992-07-02 1992-07-02
PCT/US1993/006326 WO1994001550A1 (en) 1992-07-02 1993-07-02 Self-stabilized oligonucleotides as therapeutic agents

Publications (1)

Publication Number Publication Date
DE69321122D1 true DE69321122D1 (de) 1998-10-22

Family

ID=25426596

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69321122T Expired - Lifetime DE69321122D1 (de) 1992-07-02 1993-07-02 Selbststabilisierte oligonukleotide als therapeutika

Country Status (14)

Country Link
EP (1) EP0649467B1 (de)
JP (1) JPH08501928A (de)
KR (1) KR950702626A (de)
AT (1) ATE171210T1 (de)
AU (1) AU4770093A (de)
CA (1) CA2139319A1 (de)
CZ (1) CZ333294A3 (de)
DE (1) DE69321122D1 (de)
FI (1) FI946201A0 (de)
HU (1) HUT69981A (de)
NZ (1) NZ255028A (de)
PL (1) PL172710B1 (de)
RU (1) RU94046425A (de)
WO (1) WO1994001550A1 (de)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
WO1995024477A1 (en) * 1994-03-08 1995-09-14 City Of Hope Human papillomavirus targeted ribozymes
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US20050032067A1 (en) * 2002-11-05 2005-02-10 Prakash Thazha P. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US7070925B1 (en) * 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
WO1998003646A1 (en) * 1996-07-22 1998-01-29 Hybridon, Inc. Compositions and methods for treating specific gene expression-related diseases and disorders in humans
DE19631919C2 (de) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
SG115493A1 (en) 1998-03-20 2005-10-28 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
ATE507299T1 (de) * 1998-04-08 2011-05-15 Commw Scient Ind Res Org Verfahren und mittel zum erhalt von veränderten phänotypen
US8598332B1 (en) * 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
CA2331919A1 (en) * 1998-06-23 1999-12-29 Medical Research Council Structured antisense nucleic acid molecules
ES2330812T3 (es) 1998-07-02 2009-12-15 Gen-Probe Incorporated Antorchas moleculares.
MXPA01003642A (es) * 1998-10-09 2003-07-21 Ingene Inc Sintesis enzimatica de adnss.
CA2345936A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. Production of ssdna in a cell
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
ES2213397T3 (es) * 1998-12-02 2004-08-16 I.D.M. Immuno-Designed Molecules Nuevos conjugados oligomericos capaces de transferir moleculas biologicas a las celulas.
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
FR2790757B1 (fr) * 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
AU770615B2 (en) * 1999-03-31 2004-02-26 Hybridon, Inc. Pseudo-cyclic oligonucleobases
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
US8017742B2 (en) * 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10160151A1 (de) * 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8202846B2 (en) 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
CA2408326A1 (en) * 2000-06-23 2002-01-03 E.I. Dupont De Nemours And Company Recombinant constructs and their use in reducing gene expression
US20030190635A1 (en) * 2002-02-20 2003-10-09 Mcswiggen James A. RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP1229134A3 (de) 2001-01-31 2004-01-28 Nucleonics, Inc Verwendung von post-transkriptioneller Genabschaltung zur Identifizierung von Nukleinsäuresequenzen die die Funktion einer Zelle beeinflussen
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
WO2003070917A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of myc and myb genes or genes of their respective pathways
WO2003072590A1 (en) * 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
WO2003070742A1 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
DE10133858A1 (de) * 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
ES2609014T3 (es) 2001-07-12 2017-04-18 University Of Massachusetts Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
PT1446162E (pt) 2001-08-17 2009-01-27 Coley Pharm Gmbh Agrupamentos imunoestimuladores oligonucléotidos com actividade melhorada
DE10163098B4 (de) * 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
EP2221377B2 (de) 2002-02-01 2017-05-17 Life Technologies Corporation Doppelsträngige Oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
EP1465910A4 (de) * 2002-02-20 2005-03-16 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung der genexpression von checkpointkinase-1 (chk-1) unter verwendung kurzer interferierender nukleinsäuren
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
EP1430157B1 (de) 2002-02-20 2011-08-10 Sirna Therapeutics, Inc. Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina)
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
JP2005517433A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＴＮＦおよびＴＮＦレセプタースーパーファミリー遺伝子発現のＲＮＡ干渉媒介性阻害
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
EP1476459A4 (de) * 2002-02-20 2005-05-25 Sirna Therapeutics Inc DURCH RNA-INTERFERENZ VERMITTELTE INHIBIERUNG DER EXPRESSION DES CHROMOSOMTRANSLOKATIONSGENS UNTER VERWENDUNG KURZER INTERFERIERENDER NUKLEINSÄURE (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
EP1472265A4 (de) * 2002-02-20 2005-06-15 Sirna Therapeutics Inc DURCH RNA-INTERFERENZ VERMITTELTE INHIBIERUNG DER GENEXPRESSION VON POLYCOMB GROUP PROTEIN EZH2 UNTER ANWENDUNG VON KURZER INTERFERIERENDER NUKLEINSÄURE (siNA)
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003216255A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003228667A1 (en) * 2002-04-22 2003-12-19 Sirna Therapeutics Inc. Nucleic acid mediated disruption of hiv fusogenic peptide interactions
AU2012216354B2 (en) * 2002-08-05 2016-01-14 Silence Therapeutics Gmbh Further novel forms of interfering RNA molecules
US20050042646A1 (en) 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1556402B1 (de) 2002-09-25 2011-06-22 University of Massachusetts Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
EP2272958A1 (de) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulierung von der Forkheadbox O1A-Expression
WO2005003291A2 (en) 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
CA2504929C (en) 2002-11-05 2014-07-22 Charles Allerson Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291753B2 (en) 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7078234B2 (en) 2002-12-18 2006-07-18 Monsanto Technology Llc Maize embryo-specific promoter compositions and methods for use thereof
FR2850971B1 (fr) * 2003-02-10 2006-08-11 Aventis Pharma Sa Oligonucleotide antisens inhibant l'expression de la proteine ob-rgrp et procede de detection de composes modifiant l'interaction entre la famille de la proteine ob-rgrp et le recepteur de la leptine
WO2004087878A2 (en) 2003-03-28 2004-10-14 Monsanto Technology, Llc Novel plant promoters for use in early seed development
WO2005032455A2 (en) 2003-05-23 2005-04-14 Board Of Regents Combinatorially selected phosphorodithioate aptamer targeting ap-1
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1526177A1 (de) * 2003-10-24 2005-04-27 Institut Curie Nukleinsäuren zur Beeinflussung der Tumorzell Sterblichkeit
GEP20094767B (en) 2003-10-30 2009-09-10 Coley Pharm Group Inc C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2005047300A2 (en) * 2003-11-10 2005-05-26 University Of Utah Research Foundation Improved methods and compositions for rna interference
EP1793674B1 (de) 2003-11-26 2018-05-30 University of Massachusetts Sequenzspezifische hemmung der funktion von kleiner rna
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US20060075515A1 (en) * 2004-08-11 2006-04-06 Luethy Michael H Enhanced zein reduction in transgenic corn seed
EP1713915B1 (de) 2004-02-10 2009-12-16 Sirna Therapeutics, Inc. RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER GENEXPRESSION UNTER VERWENDUNG MULTIFUNKTIONELLER siNA (SHORT INTERFERING NUCLEIC ACID)
EP1730161B1 (de) 2004-03-25 2010-09-08 California Institute Of Technology Hybridisierungskettenreaktion
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
EP1818405B1 (de) 2004-04-09 2015-06-03 Monsanto Technology, LLC Zusammensetzungen und Verfahren zur Kontrolle von Insektenbefall bei Pflanzen
AU2005244827A1 (en) * 2004-05-12 2005-12-01 Jennifer Gordon Compositions and methods for siRNA inhibition of primate polyomavirus genes
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7928217B2 (en) * 2004-05-27 2011-04-19 Alnylam Pharmaceuticals, Inc. Nuclease resistant double-stranded ribonucleic acid
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
BRPI0519690A2 (pt) * 2004-12-30 2009-03-03 Todd M Hauser composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
EP2489726A3 (de) 2005-01-12 2012-11-28 Monsanto Technology LLC Gene und ihre Verwendung zur Pflanzenverbesserung
US7727721B2 (en) 2005-03-08 2010-06-01 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
CN101198701B (zh) 2005-04-19 2013-04-24 巴斯福植物科学有限公司 单子叶植物中的淀粉胚乳特异性和/或萌芽胚特异性表达
JPWO2006132204A1 (ja) 2005-06-06 2009-01-08 アンジェスＭｇ株式会社 転写因子デコイ
US9297036B2 (en) 2005-07-01 2016-03-29 Agilent Technologies, Inc Nucleic acid probes for analysis of small RNAs and other polynucleotides
CN104357447A (zh) 2005-09-16 2015-02-18 德福根有限公司 使用RNAi控制有害生物的方法
CA2812343C (en) 2005-09-16 2017-12-12 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
CA2622660C (en) 2005-09-16 2017-11-07 Devgen Nv Transgenic plant-based methods for plant pests using rnai
US7960357B2 (en) 2005-10-07 2011-06-14 California Institute Of Technology PKR activation via hybridization chain reaction
US20100167390A1 (en) 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
EP1973940A2 (de) 2006-01-17 2008-10-01 Biolex Therapeutics, Inc. Zusammensetzungen und verfahren zur humanisierung und optimierung von n-glycanen in pflanzen
US7754475B2 (en) * 2006-01-25 2010-07-13 Agilent Technologies, Inc. Nucleic acid probes and microarrays for analysis of polynucleotides
EP2388328A1 (de) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
ES2479090T3 (es) 2006-02-10 2014-07-23 Monsanto Technology, Llc Identificación y uso de genes diana para el control de nematodos parásitos de plantas
AU2007214547B2 (en) 2006-02-13 2012-09-20 Monsanto Technology Llc Selecting and stabilizing dsRNA constructs
EP1986697B1 (de) * 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Zusammensetzungen und verfahren zur hemmung einer genverstummung durch rna-interferenz
EP2023936A4 (de) * 2006-05-05 2010-11-24 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen in bezug auf ptpr-alpha
CN101195821A (zh) 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 利用RNAi技术改良植物抗虫性的方法
EP2114981B1 (de) 2007-01-29 2013-05-08 Isis Pharmaceuticals, Inc. Verbindungen und Methoden zur Modulation der Proteinexpression
BRPI0808008B1 (pt) 2007-02-16 2016-08-09 Basf Plant Science Gmbh molécula de ácido nucleico isolada, cassete de expressão, vetor de expressão, métodos para excisão de sequências alvo de uma planta, para produzir uma planta com rendimento aumentado, e/ou tolerância a estresse aumentada, e/ou qualidade nutritional aumentada, e/ou teor de óleo aumentado ou modificado de uma semente ou broto para a planta, e, uso da molécula de ácido nucleico
US8318921B2 (en) 2007-03-01 2012-11-27 California Institute Of Technology Triggered RNAi
US9217151B2 (en) 2007-05-16 2015-12-22 California Institute Of Technology Versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
EP2179061B1 (de) * 2007-08-15 2012-10-03 Idera Pharmaceuticals, Inc. Toll-like rezeptor-modulatoren
US8497364B2 (en) 2008-02-27 2013-07-30 California Institute Of Technology Triggered RNAi
US8241854B2 (en) 2008-05-22 2012-08-14 California Institute Of Technology Triggered RNAi
US8710021B2 (en) * 2008-06-11 2014-04-29 Bionucleon S.R.L. Inhibition of HRP-3 using modified oligonucleotides
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP3260545B1 (de) 2009-04-20 2020-07-01 Monsanto Technology LLC Resistenz gegen mehrere viren in pflanzen
WO2011130371A1 (en) 2010-04-13 2011-10-20 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
US8658780B2 (en) 2010-05-18 2014-02-25 California Institute Of Technology Triggered covalent probes for imaging and silencing genetic expression
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
US8962241B2 (en) 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US8877438B2 (en) 2010-07-20 2014-11-04 California Institute Of Technology Self-assembled polynucleotide structure
KR20130137160A (ko) 2010-08-24 2013-12-16 머크 샤프 앤드 돔 코포레이션 내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
CA2822958A1 (en) 2010-12-30 2012-07-05 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
UY33853A (es) 2010-12-30 2012-07-31 Dow Agrosciences Llc ?moléculas de ácido nucleico que se dirigen a la subunidad h de la atpasa vacuolar y confieren resistencia a plagas de coleópteros?.
CN103403164A (zh) 2010-12-30 2013-11-20 陶氏益农公司 靶向rho1小gtp结合蛋白并赋予对鞘翅目有害生物的抗性的核酸分子
AU2011351946B2 (en) 2010-12-30 2017-05-18 Dow Agrosciences Llc Nucleic acid molecules that target the vacuolar ATPase C subunit and confer resistance to coleopteran pests
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
US9688983B2 (en) 2012-12-20 2017-06-27 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP2810952A1 (de) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Neuartige Schädlingsbekämpfungsverfahren
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
JP2016528897A (ja) * 2013-08-16 2016-09-23 ラナ セラピューティクス インコーポレイテッド Ｒｎａを調節するための組成物および方法
BR102014031844A2 (pt) 2013-12-20 2015-10-06 Dow Agrosciences Llc ras oposto (rop) e moléculas de ácido nucleico relacionadas que conferem resistência a pragas de coleópteros e hemípteros
CN106028838A (zh) 2013-12-20 2016-10-12 美国陶氏益农公司 赋予鞘翅目害虫抗性的rnapii-140核酸分子
EP3116998A4 (de) 2014-03-12 2017-10-11 The University Of Sydney Sirna-produktion in plastiden höherer pflanzen
CN106661590A (zh) 2014-05-07 2017-05-10 美国陶氏益农公司 赋予鞘翅目害虫抗性的dre4核酸分子
CN105087554B (zh) * 2014-05-14 2017-09-22 武汉大学 Dna磷硫酰化修饰基因簇
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
US20160194658A1 (en) 2014-12-22 2016-07-07 Dow Agrosciences Llc Nucampholin nucleic acid molecules to control coleopteran insect pests
EP3256591A4 (de) 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Hybride oligonukleotide und verwendungen davon
US20160264991A1 (en) 2015-03-13 2016-09-15 Dow Agrosciences Llc Rna polymerase i1 nucleic acid molecules to control insect pests
CA2980796A1 (en) 2015-04-13 2016-10-20 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Novel aflatoxin and fungal infection control methods
BR102016012010A2 (pt) 2015-05-29 2020-03-24 Dow Agrosciences Llc Molécula de ácido nucleico, de ácido ribonucleico (rna) e de ácido ribonucleico de filamento duplo (dsrna), usos de célula, planta e semente, produto primário, bem como métodos para controlar uma população de pragas coleópteras e/ou hemípteras, para melhorar o rendimento de uma cultura, e para produzir uma célula vegetal transgênica e uma planta transgênica
WO2017066041A2 (en) 2015-10-12 2017-04-20 Dow Agrosciences Llc Wupa nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
WO2017106126A1 (en) 2015-12-18 2017-06-22 Dow Agrosciences Llc Ribosomal protein L40 (RPL40) NUCLEIC ACID MOLECULES THAT CONFER RESISTANCE TO COLEOPTERAN AND HEMIPTERAN PESTS
IL302802A (en) 2016-07-05 2023-07-01 California Inst Of Techn Hybridization chain reaction based on a minimal initiator
CA3034617A1 (en) 2016-08-30 2018-03-08 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
WO2018089237A1 (en) 2016-11-10 2018-05-17 Dow Agrosciences Llc Cytochrome b (cytb) nucleic acid molecules that control pathogens
EP3342780A1 (de) 2016-12-30 2018-07-04 Dow AgroSciences LLC Nukleinsäuremoleküle mit prä-mrna-verarbeitungsfaktor 8 (prp8) zur kontrolle von insektenschädlingen
US11696954B2 (en) * 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
EP3825408A1 (de) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Verfahren zur insektenschädlingsbekämpfung für mehrere arten
EP4284925A1 (de) 2021-01-26 2023-12-06 California Institute of Technology Allosterische bedingte guide-rnas zur zellselektiven regulierung von crispr/cas

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3256539B2 (ja) * 1990-08-28 2002-02-12 エポック・ファーマシューティカルズ・インコーポレイテッド 連結分子を介する３’―尾分子付オリゴヌクレオチドの固体支持体合成

Also Published As

Publication number Publication date
WO1994001550A1 (en) 1994-01-20
CZ333294A3 (en) 1995-07-12
AU4770093A (en) 1994-01-31
NZ255028A (en) 1997-03-24
HU9403788D0 (en) 1995-02-28
FI946201A (fi) 1994-12-30
PL307025A1 (en) 1995-05-02
KR950702626A (ko) 1995-07-29
HUT69981A (en) 1995-09-28
PL172710B1 (pl) 1997-11-28
CA2139319A1 (en) 1994-01-20
JPH08501928A (ja) 1996-03-05
RU94046425A (ru) 1997-03-20
FI946201A0 (fi) 1994-12-30
EP0649467B1 (de) 1998-09-16
ATE171210T1 (de) 1998-10-15
EP0649467A1 (de) 1995-04-26

Similar Documents

Publication Publication Date Title
DE69321122D1 (de) Selbststabilisierte oligonukleotide als therapeutika
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
ES2086997T3 (es) Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
ATE221914T1 (de) Gegenläufige oligonukleotide mit hemmender wirkung auf tumorbildung
BR9306775A (pt) Fosforotioato e/ou fosforoditioato de oligonucleotídeo híbrido formulação farmacéutica terapéutica e processo para inibir a expressão genética de um vírus organismo patogénico ou gene celular
ZA200304500B (en) Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
ATE162198T1 (de) Oligonukleotid alkylphosphonothiate
EP0643720A4 (en) Binding competent oligomers containing 2', 5' linkages.
WO2000014217A3 (en) G-motif oligonucleotides and uses thereof
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
FR2714383B1 (fr) Contrôle de l'expression de gènes.
FI961202A (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
SE9503117D0 (sv) Novel use of padlock probes
WO1999028439A3 (fr) Erythrovirus et ses applications
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
NO945020L (no) Selv-stabiliserende oligonukleotider som terapeutiske midler
ATE318617T1 (de) Synthetische oligonukleotide als erythroid differenzierungserreger
AU2001287860A1 (en) Transglutaminase gene products
Abdula Silencing the code
EP1724351A3 (de) Menschliche Kallikrein-ähnliche Gene

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: HYBRIDON, INC., CAMBRIDGE, MASS., US

8332 No legal effect for de